Guardian Bio

YC S22 · Active · Dendritic cell-based platform for cancer therapy

Competitors

Companies closest to Guardian Bio
Company	Category	Status	Program
Granza BioShared: immune system, oncology, therapeuticsActiveOther	Other	Active	YCW24
Eris BiotechShared: immune system, oncology, therapeuticsActiveOther	Other	Active	YCW24
Kopra BioShared: immune system, oncology, therapeuticsActiveOther	Other	Active	YCS24
Modulari-TShared: immune system, oncology, biotechActiveOther	Other	Active	YCW23
AlixiaShared: oncology, therapeutics, biotechActiveOther	Other	Active	YCW22

Adjacent

Companies next to Guardian Bio
Company	Category	Status	Program
Serinus BiosciencesShared: oncology, therapeutics, biotechActiveAI	AI	Active	YCS22
Reverie LabsShared: cancer therapy, biotech, therapeuticsInactiveAI	AI	Inactive	YCW18
SynsoryBioShared: oncology, therapeutics, biotechActiveOther	Other	Active	YCW24
Adventris PharmaceuticalsShared: oncology, therapeutics, biotechActiveOther	Other	Active	YCW23
Valink TherapeuticsShared: against cancer, therapeutics, biotechActiveOther	Other	Active	YCW21

Also from S22

All of S22

Company	Category	Status
ArgovoxVoice AI agents for patient billing and collectionsInactiveAI	AI	Inactive
Birch BiosciencesWe recycle plastic using engineered enzymesActiveAI	AI	Active
KeylikaRedefining the Standard of Care for Iron Deficiency AnemiaActiveAI	AI	Active
LaminOpen data platform for traceable, multimodal AIActiveAI, Data, Devtools	AI, Data, Devtools	Active
MedplumAPI first electronic health record (EHR) that is open sourceActiveDevtools	Devtools	Active
MetriportHealthcare data infrastructure for next generation care delivery.ActiveAI, Devtools	AI, Devtools	Active

About Guardian Bio

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.

YC batch: S22 · Summer 2022
Status, per YC: Active
Category: Other
Team size: 2
Location: Boston, MA, USA
Checked: 35m ago

YC tags: Biotech, Healthcare, Therapeutics, Oncology

Guardian Bio in S22: 233 companies, 55% AI

Guardian Bio: questions

Which YC batch was Guardian Bio in?

Guardian Bio was in Y Combinator's Summer 2022 batch (S22).

Is Guardian Bio still active?

Y Combinator lists Guardian Bio as active.

Where is Guardian Bio based?

Guardian Bio lists Boston, MA, USA as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.